PYRUKYND

This brand name is authorized in Austria, France, Croatia, Ireland, Italy, Lithuania, United States

Active ingredients

The drug PYRUKYND contains one active pharmaceutical ingredient (API):

1 Mitapivat UNII N4JTA67V3O - MITAPIVAT SULFATE

Mitapivat is a pyruvate kinase activator and acts by directly binding to the pyruvate kinase tetramer. The red blood cell (RBC) form of pyruvate kinase (PKR) is mutated in PK deficiency, which leads to reduced adenosine triphosphate (ATP) levels, shortened RBC lifespan and chronic haemolysis. Mitapivat improves RBC energy homeostasis by increasing PKR activity. Read about Mitapivat

Medication package inserts

Below package inserts are available for further reading:

Title	Information Source	Document Type
PYRUKYND Film-coated tablet	European Medicines Agency (EU)	MPI, EU: SmPC

Medicine classification

This drug has been classified in the anatomical therapeutic chemical (ATC) classification system as follows:

ATC code	Group title	Classification
B06AX04		B Blood and blood forming organs → B06 Other hematological agents → B06A Other hematological agents → B06AX Other hematological agents
Discover more medicines within B06AX04

Authorization and marketing

This drug has been assigned below unique identifiers within the countries it is being marketed:

Country	Identification scheme	Identifier(s)
Country: FR	Base de données publique des médicaments	Identifier(s): 60597386, 60728501, 60861124, 62256896, 63733756
Country: IT	Agenzia del Farmaco	Identifier(s): 050445016, 050445028, 050445042, 050445055, 050445067
Country: LT	Valstybinė vaistų kontrolės tarnyba	Identifier(s): 1095946, 1095947, 1095948, 1095949, 1096042, 1096043
Country: US	FDA, National Drug Code	Identifier(s): 71334-205, 71334-210, 71334-215, 71334-220, 71334-225, 71334-230